Filed
Pursuant to Rule 424(b)(5)
Registration
No. 333−130809
Prospectus
Supplement
(To
Prospectus dated January 13, 2006)
4,500,000 SHARES
Keryx
Biopharmaceuticals, Inc.
COMMON
STOCK
We
are
offering up to 4,500,000
shares
of our common stock directly to selected institutional investors pursuant to
this prospectus supplement and the accompanying prospectus. The common stock
will be purchased at a negotiated price of $18.40
per
share. Assuming the sale of all 4,500,000
shares
offered by this prospectus supplement and the accompanying prospectus, the
offering will result in total proceeds (before expenses) to the company of
82,800,000.
There
are no underwriting or placement agent fees associated with the
offering.
Our
common stock trades on the Nasdaq National Market under the symbol “KERX.” On
March 23,
2006,
the last reported sales price of our common stock on the Nasdaq National Market
was $18.40
per
share.
Investing
in our common stock involves risks. See “Risk Factors” beginning on page 18 of
our annual report on Form 10-K, which is incorporated into the prospectus and
this prospectus supplement.
The
net
proceeds from any sales under this prospectus supplement will be used as
described under “Use of Proceeds” in this prospectus.
_____________________________________
Neither
the Securities and Exchange Commission nor any state securities commission
has
approved or disapproved of these securities or determined if this prospectus
is
truthful or complete. Any representation to the contrary is a criminal
offense.
_____________________________________
March
24,
2006